Prevalence of drug interactions in the Department of Internal Medicine at Hospital Universitario Hernando Moncaleano Perdomo-cross sectional study
##plugins.themes.bootstrap3.article.sidebar##
PDF (Español (España))
FLIP
HTML (Español (España))
##plugins.themes.bootstrap3.article.main##
Objectives. To characterize drug interactions that took place at University Hospital Hernando Moncaleano Perdomo. Material and methods. Cross sectional descriptive study, with 130 patients admitted to Department of Internal Medicine located on the sixth floor of HUHMP Data analysis was carried outwith epi.Infov7.0. Results. It was found 702 theoretical interactions. There as a median of 3 interactions per patient. 73% of patients had a drug interaction,from which 93.3 were significant. Most frequent diagnosis were: HBP (HighBloodPressure) (12.3%), followed by neoplasm (11.5%), heartfailure (8.4%), type 2 diabetes mellitus (6.9%), CVE (cerebro-vascularevent) ischemic (3.8%), acute myocardial infarction (3.8%), heartdisease (3.1%), chronic kidney disease (3.8%),sepsis (7.7%), and tensión headache(6.2%). Conclusions. Pharmacodynamic interactions represent 71.8% of all data and the most frequent were those of synergism with potentiation (55.2%).
Downloads
##plugins.themes.bootstrap3.article.details##
Shiew MH, Lawrence J, Temple R. Efectos secundarios e interacciones de los fármacos. En: Waldman SA, Terzic A, editores. Farmacología y terapéutica, principios de la práctica clínica. México: manual moderno. 2010; p: 265-272.
Osterhoudt KC, Penning TM. Toxicidad e intoxicaciones por fármacos. En: Goodman y Gilman. Las bases farmacológicas de la terapéutica. Mc Graw Hill. 12 edición. 2011; p. 73-87.
Wilkinson GR. Drug metabolism and variability among patient s in drug response. New England Journal of Medicine 2005;(352):2211-2221.
Gonzalez FJ, Coughtrie M, Tukey RH. Metabolismo de los fármacos. En: Goodman y Gilman. Las bases farmacológicas de la terapéutica. Mc Graw Hill. 12 edición. 2011; p. 123-143.
Becker ML, Visser LE, et al. Increasing exposure to drug – drug interaction between 1992 and 2005 in people aged > or = 55 year. Drugs Aging 2008;(2):145-152.
Doan J, Zakrzewski JH, Roy J. Prevalence and risk of potential cytochrome P450 mediated Drug-Drug interactions in older hospitalized patients with polypharmacy. The annals of Pharmacotherapy. 2013;47:324-332.
Bonilla JD. Prevalence and risk factors related to bleeding of patients when undergoing warfarina therapy at Hernando Moncaleano Perdomo Hospital in Neiva in 2011; Revista Facultad de Salud; Julio-Diciembre 2011;3(2):23-31.
Zwart-Van R Jeannette EF. Frequency and nature of drug– drug interactions in a Dutch university hospital. Journal compilation. The British Pharmacological Society. 2009;68(2):187-193.
Greenblatt DJ. Preparation of Scientific Reports on Pharmacokinetic Drug Interaction Studies. Journal of Clinical Psychopharmacology. 2008;28(4):369-373.
Machado JE, Giraldo C. Farmacovigilancia de interacciones medicamentosas en pacientes afiliados al sistema de salud de Colombia. INVESTIGACIONES ANDINA, No. 22; 2011(13):151-161.
Colimon KM. Tamaño Muestral. En: Fundamentos de epidemiología. Corporación para investigaciones biológicas. Tercera edición; 2010, p. 176-181.
http://reference.medscape.com/drug-interactionchecker
CF, Menéndez OM, Rivero M, Yodu M. Importancia clínica de las interacciones medicamentosas. Revista Cubana Hig Epidemiología 2000;38(1):48-52.
Syed S Hasan, See C Keong, Christopher LK Choong. Patient reported adverse drug reactions and drug-drug interactions: a cross-sectional study on Malaysian HIV/AIDS patients. Medical Principles and Practice. 2011;(20):265-270.
Jankel F, Saha L, Pandhi P, Malhotra S. Adverse Drug Event (ADE) related Medical Emergency Department visits and hospital admissions: a prospective study from a North Indian Referral Hospital. Journal of Clinical and Diagnostic Research 2008;2(1):600-604.
Daniel E. Becker. Pharmacodynamic Considerations for Moderate and Deep Sedation. Anesthesia Progress: Spring 2012;59(1):28-42.
Andersson ML, Böttiger Y et al. Impact of the drug – drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care. European journal clinical pharmacology 2013;(69):565-571.
Buckley M, Kazem N, Wicks L et al. Clinical decision support drug drug interaction alert overrides: A comparison between intensive care. Critical care medicine 2013;41(12).
Cremades J, Gonzalo M, Arrebola S. Relationship between drug interactions and drug related negative clinical outcomes in two community pharmacies.
